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Objectives This study sought to determine the effect of rotational atherectomy (RA) on drug-eluting
stent (DES) effectiveness.
Background DES are frequently used in complex lesions, including calciﬁed stenoses, which may
challenge DES delivery, expansion, and effectiveness. RA can adequately modify calciﬁed plaques
and facilitate stent delivery and expansion. Its impact on DES effectiveness is widely unknown.
Methods The ROTAXUS (Rotational Atherectomy Prior to TAXUS Stent Treatment for Complex Native
Coronary Artery Disease) study randomly assigned 240 patients with complex calciﬁed native coronary
lesions to RA followed by stenting (n  120) or stenting without RA (n  120, standard therapy group).
Stenting was performed using a polymer-based slow-release paclitaxel-eluting stent. The primary end-
point was in-stent late lumen loss at 9 months. Secondary endpoints included angiographic and strategy
success, binary restenosis, deﬁnite stent thrombosis, and major adverse cardiac events at 9 months.
Results Despite similar baseline characteristics, signiﬁcantly more patients in the standard therapy
group were crossed over (12.5% vs. 4.2%, p  0.02), resulting in higher strategy success in the rotabla-
tion group (92.5% vs. 83.3%, p  0.03). At 9 months, in-stent late lumen loss was higher in the rotabla-
tion group (0.44  0.58 vs. 0.31  0.52, p  0.04), despite an initially higher acute lumen gain (1.56 
0.43 vs. 1.44  0.49 mm, p  0.01). In-stent binary restenosis (11.4% vs. 10.6%, p  0.71), target lesion
revascularization (11.7% vs. 12.5%, p  0.84), deﬁnite stent thrombosis (0.8% vs. 0%, p  1.0), and major
adverse cardiac events (24.2% vs. 28.3%, p  0.46) were similar in both groups.
Conclusions Routine lesion preparation using RA did not reduce late lumen loss of DES at 9
months. Balloon dilation with only provisional rotablation remains the default strategy for complex
calciﬁed lesions before DES implantation. (Rotational Atherectomy Prior to Taxus Stent Treatment for
Complex Native Coronary Artery Disease. A Multicenter, Prospective, Randomized Controlled Trial
[ROTAXUS]; NCT00380809) (J Am Coll Cardiol Intv 2013;6:10–9) © 2013 by the American College of
Cardiology Foundation
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11Drug-eluting stents (DES) have substantially reduced re-
stenosis rates in randomized clinical trials evaluating simple
de novo coronary artery lesions (1–5). DES have also shown
favorable results when implanted in complex lesions and
patients (6), but higher event rates are observed when
treating such subsets compared with simple patients even
with newer generation DES (7). To obtain the desired
long-term effectiveness of DES, successful initial implanta-
tion must be accomplished, which occasionally makes ag-
gressive lesion preparation essential in patients with com-
plex anatomy (8). Heavily calcified lesions present a special
challenge due to their resistant plaque burden, which may
lead to failure of stent delivery or expansion and, therefore,
may increase the likelihood of stent thrombosis and/or
restenosis. Moreover, heavily calcified lesions may form a
particular threat to DES; both damage to the polymer/drug
coating during vigorous advancement and inadequate diffu-
sion of the drug to the subintima through extensive calcium
arcs could contribute to ineffectiveness of DES when
implanted into such lesions.
Rotational atherectomy (RA) can effectively ablate calci-
fied plaques, facilitating in many cases stent delivery and
expansion. However, late restenosis remains high when it is
used as a stand-alone therapy or when combined with
bare-metal stents (9,10). Recently, some observational
studies suggested a favorable long-term outcome of RA
followed by DES implantation (11–15). Theoretically,
RA and DES could act synergistically in complex lesions
as RA could avert stent coating damage and DES could
effectively suppress neointimal proliferation. Therefore,
RA of heavily calcified lesions may improve the efficacy of
DES, but this concept is not supported by randomized
controlled studies.
Methods
Patients and study design. ROTAXUS (Rotational
Atherectomy Prior to TAXUS Stent Treatment for Com-
plex Native Coronary Artery Disease) is a randomized
active-controlled superiority trial in patients with docu-
mented myocardial ischemia and complex calcified native
coronary artery lesions. The trial was performed at 3
high-volume, experienced interventional study sites in Ger-
many. The participating centers and investigators were
selected on the basis of experience with percutaneous
coronary intervention (PCI) and RA. Procedures were
performed by fully trained operators with at least 50 prior
rotablation procedures and several years of interventional
experience.
Between August 2006 and March 2010, 240 eligible
patients who gave written informed consent were random-
ized 1:1 to a strategy of rotablation followed by stenting or
stenting without prior rotablation (standard therapy). Stent-
ing was performed using the polymer-based slow-releasepaclitaxel-eluting Taxus Liberté stent (paclitaxel-eluting
stents [PES]; Boston Scientific, Boston, Massachusetts).
Inclusion and exclusion criteria are shown in Tables 1 and 2
16). The study was conducted in accordance with the
rovisions of the Declaration of Helsinki and with the
nternational Conference on Harmonization Good Clinical
ractices. The trial protocol was approved by the institu-
ional ethics committee of the 3 participating centers.
Randomization and procedures. Randomization was carried
out through computer-generated block randomization
forms for each participating center. After the patient pro-
vided a written informed consent, a numbered envelope was
opened, assigning the patient to either RA and stenting or
stenting without rotablation in a 1:1 randomization fashion.
The date of randomization marked the patient’s entry into
the study, and the assigned interventional technique had to
be performed as soon as possible.
After the decision to perform
intervention, patients received
325 to 500 mg of aspirin intra-
venously or orally (if they did not
receive it within the prior 12 h)
and an oral loading dose of 600
mg of clopidogrel. Immediately
before intervention, intra-arterial or
intravenous heparin was given to
maintain an activated clotting
time 250 s, or 200 to 250 s if a
glycoprotein IIb/IIIa receptor
blocker had been administered.
The use of glycoprotein IIb/IIIa
antagonists, other antithrom-
botics (e.g., bivalirudin), and
further cardiac medications was
left to the discretion of the treat-
ing physician.
Coronary angiography was
performed according to the conventional and local stan-
dards. Percutaneous intervention was either performed in
the same setting, if the patient had consented to the study
before the procedure and angiographic eligibility had been
determined, or performed in a separate setting. In case of
multivessel disease, all other vessels should have been
successfully treated before the assigned treatment is applied
to the target vessel(s). This was done either in the same
setting or in a previous setting.
Rotablation was performed by the Rotablator (Boston
Scientific Scimed, Maple Grove, Minnesota). The burr size
was selected to reach a burr/vessel ratio of 0.5 (maximum:
0.7 if needed). Rotablation speed ranged between 140,000
and 180,000 rotations per minute. The burr was platformed
immediately proximal to the lesion to avoid injury to the
healthy vessel segment. Heparin, verapamil, and nitroglyc-
Abbreviations
and Acronyms
CK  creatine kinase
DES  drug-eluting stent(s)
LLL  late lumen loss
MI  myocardial infarction
PCI  percutaneous
coronary intervention
PES  paclitaxel-eluting
stent(s)
RA  rotational atherectomy
TIMI  Thrombolysis In
Myocardial Infarction
TLR  target lesion
revascularization
TVR  target vessel
revascularizationerin were administered during rotablation as an intracoro-
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12nary infusion, and a temporary pacemaker wire was inserted
during rotablation of the right coronary artery and the left
circumflex artery in patients with a dominant left system.
Stent delivery was performed in all patients using exclu-
sively PES. More than 1 study stent was permitted for
treatment of the target lesion(s). The appropriate stent
length for the target lesion should have been4 mm longer
than the lesion length to allow for coverage between healthy
vessel segments, with adequate stent overlapping. Post-
dilation was performed at the operator’s discretion. Upon
procedure completion, intracoronary nitroglycerin was ad-
ministered and final angiography of the vessel was per-
formed in at least 2 orthogonal views that showed the target
site to be free of foreshortening or vessel overlap.
Follow-up and endpoints. All patients received 100 mg of
aspirin daily indefinitely and 75 mg of clopidogrel for at
least 6 months. An electrocardiogram was performed 24 h
after the procedure or before discharge, whichever occurred
first. Additional 12-lead electrocardiograms were required
to document any suspicious cardiac ischemic episodes.
In addition, creatine kinase (CK) and creatine kinase-
myocardial band (CK-MB) were measured after the proce-
dure between 8 and 12 h. If any CK elevation was noted
after the procedure, additional measurements were per-
formed, as needed. During their hospital stays, patients were
clinically monitored for the occurrence of any adverse events
and any additional coronary interventional treatment. At 9
months, a clinic visit and a repeat coronary angiography
were performed. Off-line quantitative and qualitative anal-
yses of all angiographic parameters were performed by the
Table 1. Inclusion Criteria
Clinical Inclusion Criteria
1. Age above 18 years
2. Angiographically proven coronary artery disease
3. Angina II to IV following the Canadian Cardiovascular Society classiﬁcation cri-
teria and/or reproducible ischemia in the target area by ECG or scintigraphy
4. The patient signing an informed written consent
Angiographic Inclusion Criteria*
First-degree criteria
1. De-novo lesion in a native coronary artery
2. Target reference vessel diameter between 2.5 and 4.0 mm by visual
estimation
3. Luminal diameter reduction of 70% to 99% by visual estimation
4. Moderate to severe calciﬁcation of the target lesion†
Second-degree criteria
1. Ostial location
2. Bifurcational lesions
3. Long lesions (15 mm)
*Lesions had to fulfill all first-degree criteria and at least 1 second-degree criterion to be eligible
for inclusion. †Coronary calcium was angiographically graded as follows: none/mild; moderate
(radiopacities noted only during the cardiac cycle before contrast injection); and severe (ra-
diopacities notedwithout cardiacmotionbefore contrast injection generally compromisingboth
sides of the arterial lumen) (16).
ECG electrocardiogram.angiographic core laboratory. All major cardiac events wereadjudicated by the clinical event adjudication committee
(see Online Appendix).
The primary endpoint of the trial was the in-stent late
lumen loss (LLL) at 9 months, defined as the difference
between the immediate post-procedure in-stent minimal
lumen diameter and the in-stent minimal lumen diameter at
9-month follow-up angiography. Secondary endpoints in-
cluded major adverse cardiac events defined as a composite
of death, new myocardial infarction (MI) and target vessel
revascularization (TVR) at 9 months, target lesion revascu-
larization (TLR), stent thrombosis (definite), in-segment
LLL (inside the stent or within 5 mm proximal or distal to
the stent), binary restenosis (in-stent and in-segment),
angiographic success, strategy success, procedural duration,
and contrast amount. Death was defined as all-causes of
mortality. MI was defined as elevated CK 3 the upper
limit of normal with elevated CK-MB (any amount above
the institution’s upper limit of normal) in the absence of
new pathological Q waves (non–Q-wave MI), or as chest
pain or other acute symptoms consistent with myocardial
ischemia and/or new pathological Q waves in 2 or more
contiguous electrocardiogram leads in the absence of timely
cardiac enzyme data and/or new pathological Q waves in 2
or more contiguous leads and elevation of cardiac enzymes
(Q-wave MI). TVR was defined as a repeated procedure,
either PCI or bypass surgery, on the target vessel, and TLR
was defined as any reintervention inside the stent implanted
during the index procedure or within 5 mm proximal or
distal to the stent. Stent thrombosis was defined as proposed
by the Academic Research Consortium (17). Angiographic
success was defined as successful stent delivery and expan-
sion with attainment of 20% in-stent residual stenosis of
the target lesion in the presence of TIMI (Thrombolysis In
Myocardial Infarction) flow grade 3, whereas strategy suc-
cess was defined as angiographic success without crossover
or stent loss.
Quantitative angiographic analysis. Baseline, post-
procedural, and follow-up coronary angiograms were digi-
tally recorded and assessed off-line in the quantitative
angiographic core laboratory (ISARESEARCH Center,
Munich, Germany) with an automated edge-detection sys-
tem (CMS version 7.1, Medis Medical Imaging Systems,
Table 2. Exclusion Criteria
Clinical Exclusion Criteria
1. Myocardial infarction within 4 weeks
2. Left ventricular ejection fraction 30%
3. Limited long-term prognosis due to other conditions
Angiographic Exclusion Criteria
1. Unprotected left main lesions
2. Coronary artery bypass graft stenoses
3. In-stent restenoses
4. Chronic total occlusions
5. Target vessel thrombus
6. Target vessel dissection
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13Leiden, the Netherlands) by an independent experienced
operator unaware of the treatment allocation. Measure-
ments were performed on cineangiograms recorded after the
intracoronary administration of nitroglycerine using the
same single worst-view projection at all times. The contrast-
filled nontapered catheter tip was used for calibration.
Quantitative analysis was performed on both the in-stent
and in-segment areas (including the stented segment, as
well as both 5-mm margins proximal and distal to the stent).
Intraobserver variability was calculated at 0.09  0.07 mm
for the measurement of vessel size. Qualitative morpholog-
ical lesion characteristics were characterized by standard
criteria.
Statistical analysis. We assumed an LLL of 0.5  0.5 mm
n patients assigned to the group without RA and a 40%
eduction (LLL of 0.3 mm) in patients assigned to RA
ccording to results of initial observational studies (11). On
his basis, 198 patients/lesions were needed to provide an
0% power to detect this reduction at a 2-sided alpha-error
evel of 0.05. To account for the expected dropouts at
ollow-up, the total patient number for the study was set at
40 patients.
All statistical analyses were performed by the statistical
ore institute in a blinded manner regarding the ran-
omly assigned treatment and on an intention-to-treat
asis. Continuous data are presented as mean  SD or
median (interquartile range). Categorical data are pre-
sented as counts and proportions (%). We tested data
distribution for normality using the Kolmogorov-
Smirnov test for goodness of fit. For patient-level data,
differences between groups were checked for significance
240 patients enrolled bet
clinic
RA + PES  
(N=120)
240 patients analyzed
- 2 patients died in-hospital
- 6 patients withdrew consent
Clinical follow-up at 9 
months in 96.2% (N=227
   
- 5 patients lost at follow-up
Figure 1. Study Flow ChartPES  paclitaxel-eluting stent(s); RA  rotational atherectomy.with Student t test or Wilcoxon rank-sum test (contin-
uous data) or the chi-square or Fisher exact test when the
expected cell value was less than 5 (categorical variables).
For lesion-level data, differences between groups were
checked for significance with generalized estimating
equations to address intrapatient correlation in patients
who underwent multilesion intervention. All tests were
2-sided and a p value of 0.05 was considered statistically
significant. No adjustment was made for the primary and
secondary endpoint comparisons. Event-free survival was
assessed using Kaplan-Meier method. The study chair
and principal investigators vouch for the accuracy and
completeness of the reported data.
Results
Baseline clinical and angiographic characteristics. Of 240
patients enrolled in the study, 120 patients (86 men, 70.5 
8.2 years) were randomized to rotablation followed by PES
(RA  PES group) and 120 patients (96 men, 71.8  7.2
years) to PES without prior rotablation (standard therapy
control group). The study flow chart is summarized in
Figure 1. There were no clinically relevant differences
between both groups with respect to clinical presentation
(mostly stable angina), cardiovascular risk factors, preva-
lence of chronic renal failure, or history of myocardial
infarction (Table 3). Multivessel disease was common and
was present in 74% of either group. Overall, 322 lesions
were treated: 146 in the RA  PES group and 172 in the
standard therapy group. Patients were also well balanced
according to lesion location and morphology (Table 4). The
 August 2006 and March 2010 at 3 
tes in Germany
domization
Standard therapy 
(N=120)
 complete in-hospital follow-up 
Angiographic follow-up at 9 
months in 80.5% (N=190)ween
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14target lesions were of high-grade stenosis (diameter stenosis
by visual estimate 81.5  10.2% in the RA  PES group
and 80.0  10.8% in the standard therapy group) and, in
accordance with the angiographic inclusion criteria, were
quite complex (46.9% with heavy calcifications, 46.6% with
moderate or severe tortuosity, 47.8% at bifurcations, and
89.8% type B2/C lesions). Lesions treated in the RA PES
group were slightly longer by visual estimation (20.6  9.3
mm vs. 18.5  9.2 mm, p  0.04) and were more
commonly type B2/C lesions (93.8% vs. 86.3%, p  0.15).
Procedural details and outcome. Procedural details are
shown in Table 4. Only 20 procedures (8.3%) were per-
formed as an ad hoc PCI. Most RA procedures (83.6%)
were performed through a 7-F guiding catheter, whereas
most standard procedures (71.6%) were performed through
a 6-F guiding catheter. Balloon pre-dilation was performed
in most lesions with a similar mean balloon size in both
groups (2.6  0.4 mm in the standard therapy group and
2.5  0.3 mm in the RA  PES group), but the mean
inflation pressure was higher in the standard therapy group
(15.8  4.9 atm vs. 13.6  5.1 atm, respectively; p 
0.003). For rotablation, a single burr was used in most
lesions (94.5%) with a mean burr size of 1.5 0.2 mm. The
mean stent length/lesion was well beyond the mean lesion
Table 3. Baseline Characteristics (N  240 Patients)
RA  PES
(n  120)
Standard Therapy
(n  120) p Value
Age, yrs 70.5 8.2 71.8 7.2 0.20
Men 86 (72.3) 96 (81.7) 0.13
BMI, kg/m2 27.9 4.3 27.8 4.0 0.68
Diabetes mellitus 33 (27.7) 32 (26.8) 0.88
Hypertension 106 (89.1) 95 (79.8) 0.05
Dyslipidemia 91 (76.5) 87 (73.1) 0.55
Current smokers 24 (20.2) 16 (13.5) 0.17
Family history of CAD 39 (32.8) 44 (37.0) 0.50
Chronic renal failure 5 (4.2) 8 (6.7) 0.40
Previous MI 38 (31.9) 29 (24.4) 0.20
Previous PCI 44 (37.0) 39 (32.8) 0.50
Previous CABG 9 (7.6) 15 (12.6) 0.20
Unstable angina 17 (14.3) 16 (13.4) 0.85
Left main disease 11 (9.2) 8 (6.7) 0.47
Multivessel disease 88 (74.0) 88 (74.0) 0.99
LV ejection fraction, % 55.5 10.6 53.0 11.5 0.10
Ad hoc PCI 11 (9.3) 9 (7.6) 0.64
Multilesion PCI 23 (19.3) 32 (27.1) 0.16
Unfractionated heparin 49 (41.2) 70 (50.4) 0.15
Bivalirudin 70 (58.8) 59 (49.6) 0.15
GP IIb/IIIa antagonists 4 (3.4) 0 0.12
Values are n (%) or mean SD.
BMI bodymass index; CABG coronary artery bypass graft; CAD coronary artery disease;
GP glycoprotein; LV left ventricle; MImyocardial infarction; PCI percutaneous coronary
intervention; PES paclitaxel-eluting stent(s); RA rotational atherectomy.length. After stenting, balloon post-dilation was performed wfor almost two-thirds of treated lesions in both groups
(Table 4).
Procedural complications and outcome are shown in
Table 5. Coronary dissections, perforations, and no-/slow-
flow phenomena were rare and occurred equally in both
groups, but procedural and fluoroscopy times were longer in
the rotablation group. The intention-to-treat analysis re-
vealed an identical angiographic success rate (96.7%) for
both groups. Three cases of stent loss were recorded, all in
the standard therapy group; 1 of these developed a peripro-
cedural transient ischemic attack. In addition, there were 15
(12.5%) crossovers from standard therapy to rotablation
because of failure of balloon or stent delivery or suboptimal
balloon expansion despite the use of a noncompliant bal-
loon. The reason for crossover of 5 (4.2%) patients from
rotablation to standard PCI was a protocol deviation in 3
patients, failure of rotablation wire passage in 1 patient, and
total occlusion of the target vessel at the time of PCI in 1
patient. As a result, overall strategy success was significantly
higher in the rotablation group (92.5% vs. 83.3%, p 0.03).
In-hospital outcome. There were 2 deaths during hospital-
ization, and both occurred in the RA  PES group. One
patient died within 24 h during emergency surgery for a
large coronary perforation, and the second patient died 5
days after PCI because of massive pulmonary embolism.
Target vessel re-PCI during hospitalization became neces-
sary in 1 patient in each group. The incidence of protocol-
defined periprocedural MI was low in both groups (1.7% in
the RA  PES group vs. 3.4% in the standard therapy
roup), but access site complications were numerically
igher in the rotablation group (5.9% vs. 1.7%, respectively;
 0.17) (Table 5). Post-procedural troponin T levels (8
o 24 h after PCI) were analyzed in 172 patients with
ormal baseline values and showed a similar incidence of
ny troponin T elevation (45.1% vs. 50%, p  0.52) and
roponin T elevation 3 above the upper limit of
ormal (24.4% vs. 32.2%, p  0.26) in the RA and
tandard therapy groups, respectively.
Nine-month clinical outcome. Complete follow-up over 9
onths was available for 227 of 240 patients (96.2%) (n 
13 of the RA  PES group and n  114 of the standard
herapy group); median follow-up duration was not different
n both groups (279.5 vs. 301.0 days, respectively; p 0.15).
t 9 months, overall mortality was 5.0% versus 5.8% in the
A PES versus standard therapy group, respectively (p
.78). MI occurred in 6.7% versus 5.8% (p  0.79) and
VR in 16.7% versus 18.3% (p 0.73) of patients, resulting
n a cumulative major adverse cardiac events rate of 24.2%
ersus 28.3% in the RA  PES versus standard therapy
roup, respectively (p  0.46). Cumulative incidence curves
or death, MI, TVR, and major adverse cardiac events are
hown in Figure 2. TLR occurred in 11.7% versus 12.5%
p  0.84), and a single case of definite stent thrombosis
as observed in the rotablation group.
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15Quantitative angiographic analysis. Details of baseline
quantitative coronary angiographic analysis are listed in
Table 6. Baseline minimal lumen diameter was slightly
smaller in the rotablation group, but residual diameter
stenosis of the stented segment was significantly less (10.79 
5.61% vs. 12.34  7.85%, p  0.04) and acute gain was
significantly higher (1.56  0.43 mm vs. 1.44  0.49 mm,
p  0.01) in the rotablation group.
The 9-month angiographic follow-up is determined on
the basis of 190 patients (80.5%); 98 patients (123 lesions)
randomized to the RA  PES group and 92 patients (132
lesions) randomized to the standard therapy group. The
only differences observed between patients with and those
without angiographic follow-up is that the latter were older
(75.3  5.7 years vs. 70.0  7.8 years, p  0.001) and more
commonly women (38.8% vs. 19.6%, p  0.005). Details of
the follow-up quantitative coronary angiographic analysis
are shown in Table 7. At 9 months, in-stent LLL (the
primary endpoint) was 0.44  0.58 mm in the RA  PES
group and 0.31  0.52 mm in the standard therapy group
(p  0.04). In-segment LLL was numerically higher in the
rotablation group (0.36  0.57 mm vs. 0.25  0.57 mm,
Table 4. Angiographic and Procedural Characteristic
RA  P
Location
Left main, protected
Left anterior descending 1
Left circumﬂex
Right coronary artery
Reference vessel diameter, mm 3
Lesion length, mm 20
Diameter stenosis, % 81
Ostial location
Bifurcation
Moderate/severe tortuosity
Severe calciﬁcation
B2/C lesion 1
7-F guiding catheter 1
Balloon pre-dilation 1
Maximum pre-dilation balloon size, mm 2
Maximum pre-dilation balloon pressure, atm 13
Starting burr size, mm 1
Maximum burr size, mm 1
Use of 1 burr
Rotational speed, RPM 165,9
No. of stents/lesions 1
Total stent length/lesions, mm 27
Balloon post-dilation
Maximum post-dilation balloon size, mm 3
Maximum post-dilation balloon pressure, atm 21
Values are n (%) or mean SD.
RPM rotations per minute; other abbreviations as in Table 3.p  0.11). Binary restenosis (both in-stent and in-segment)was similar in both groups. The results of the primary
endpoint were consistent in lesions with moderate calcifi-
cation (LLL: 0.42  0.55 mm in the RA  PES group vs.
0.33  0.46 mm in the standard therapy group, p  0.32)
and in those with severe calcification (0.48  0.62 mm in
the RA  PES group vs. 0.28  0.58 mm in the standard
therapy group, p  0.07).
Discussion
Practice guidelines recommend the use of RA for preparation
of heavily calcified or severely fibrotic lesions that cannot be
crossed by a balloon or adequately dilated before planned
stenting (bailout situations) (18,19). The aim of ROTAXUS
was to explore a potentially new indication for RA by evalu-
ating whether routine elective rotablation of complex calcified
lesions could improve DES efficacy. The principal finding of
the study is that RA before PES implantation was not superior
to PES implantation without prior rotablation in reducing the
primary endpoint of in-stent LLL at 9 months, indicating that
rotablation does not increase the efficacy of DES in this
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16RA is an essential technique with growing importance in
the current PCI era as increasingly complex patients and
lesions are considered for interventional therapy. Particu-
larly in heavily calcified lesions, stent delivery and expansion
are often difficult or even impossible without RA. More-
over, heavily calcified lesions may form a special threat to
DES; both damage to the polymer/drug coating (20) and
inadequate drug diffusion through extensive calcification
may decrease DES effectiveness when implanted into such
lesions. By contrast, RA causes additional vessel injury with
increased neointimal growth. Restenosis rates after rotabla-
tion of calcified lesions are 2 to 3 higher than for
noncalcified lesions and remain unacceptably high even after
stenting in studies conducted in the pre-DES era (10,21–23).
This could be prevented by an antiproliferative drug coating
of the implanted stent; therefore, RA and DES may act
synergistically in complex calcified lesions. In this context,
Nakamura et al. (24) described an advantage of RA before
implanting sirolimus-eluting stents in terms of long-term
clinical and angiographic outcomes compared with implant-
ing sirolimus-eluting stents without prior rotablation among
long lesions, which may be interpreted as an add-on effect in
the RA  DES arm.
ROTAXUS is the first randomized controlled trial to
valuate a strategy of routine RA before DES implantation
n complex calcified coronary lesions, and we could not
emonstrate superior effectiveness of the RA  DES
strategy. The reasons for this finding were 2 unexpected
Table 5. Procedural and In-Hospital Outcome (N  240 Patients)
RA  PES
(n  120)
Standard Therapy
(n  120) p Value
Procedural duration, min 66.4 44.5 57.4 34.5 0.05
Fluoroscopy time, min 22.8 21.9 18.1 16.7 0.04
Contrast amount, ml 201.0 113.6 181.8 93.6 0.11
Dissections 4 (3.3) 4 (3.3) 0.99
Perforations 2 (1.7) 1 (0.8) 0.56
Cardiac tamponade 1 (0.8) 1 (0.8) 0.99
No/slow ﬂow 0 (0) 1 (0.8) 0.32
Persistent advanced AV block 1 (0.8) 0 (0) 0.99
Angiographic success* 116 (96.7) 116 (96.7) 0.99
Stent loss 0 (0) 3 (2.5) 0.08
Crossover 5 (4.2) 15 (12.5) 0.02
Strategy success* 111 (92.5) 100 (83.3) 0.03
Death 2 (1.7) 0 (0) 0.50
Myocardial infarction 2 (1.7) 4 (3.4) 0.68
Target vessel re-PCI 1 (0.8) 1 (0.8) 0.99
CABG 1 (0.8) 0 (0) 0.99
MACE* 5 (4.2) 5 (4.2) 0.99
Stent thrombosis 0 (0) 0 (0) 0.99
Access site complications 7 (5.9) 2 (1.7) 0.17
Values are n (%) or mean SD. *See text for definition.
AV atrioventricular; MACEmajor adverse cardiac events; other abbreviations as in Table 3.observations: 1) the LLL in the control group was lowerthan assumed; and 2) the LLL in the RA group was higher
than assumed. The 0.31-mm LLL in the control cohort was
even below the LLL pattern known from various TAXUS
trials (1–4). Obviously, lesion morphology did not impair
PES effectiveness, which could be attributed to the fact that,
although not demanded by the protocol, an aggressive lesion
preparation with high-pressure balloon dilation was applied
in more than 90% of the lesions before PES implantation.
Pre-dilation with pressures higher than those in the RA
group might have mitigated potential damage of the drug
coating during stent placement and allowed sufficient stent
expansion despite the presence of calcium. Nevertheless, a
considerable number of patients could not be treated suc-
cessfully by balloon dilation before stenting and had a stent
loss and/or had to crossover to RA. By contrast, the LLL of
0.44 mm in the RA group is an acceptable value in terms of
previous TAXUS trials (1–4). PES, however, did not
obviate the additional RA associated vessel injury and
neointimal formation, and all late angiographic outcome
measures (minimal lumen diameter and percentage of di-
ameter stenosis) were consistently poorer in the RA arm.
From an angiographic perspective, the superior acute gain
obtained by RA was counterbalanced by an increased late
loss resulting in a neutral effect on restenosis. Ultimately,
the angiographic and clinical restenosis rate is DES-like
(i.e., near 10%), which is far below the numbers in the
RA–bare-metal stent era (10) and is confirming several
observational studies on RA and DES with positive acute
and long-term outcomes (11–15).
One might speculate about potential factors within the
study protocol that were unfavorable for RA. First, it is
possible that a patient population with an even higher
fraction of severely calcified lesions can obtain more benefit
from the RA  DES concept. In ROTAXUS, more than
50% of the patients had angiographically moderate calcifi-
cation, which might be a lesion quality not requiring RA. It
is also possible that an intravascular ultrasound-guided
intervention would have offered a more appropriate lesion
selection. Nevertheless, according to the American College
of Cardiology/American Heart Association lesion morphol-
ogy classification, ROTAXUS comprised the most complex
population ever included in a randomized stent study.
Second, it might be argued that the RA strategy that was
applied in ROTAXUS does not provide sufficient plaque
ablation with a mean burr size of 1.5 mm and a burr-to-
vessel ratio of 0.5. A previous study, however, has docu-
mented a more favorable long-term outcome with our less
aggressive RA strategy (25). Third, it is conceivable that the
ROTAXUS results could have differed if another DES
system had been used. The Taxus stent was the workhorse
DES at the time of study initiation with numerous pub-
lished studies and registries, which allows us to evaluate our
results within the framework of this large data pool. Fourth,
it is possible that the observation period was too short to
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17detect an advantage of the RADES approach. In general,
TLR rates continuously increase over time in patients who
have received a DES (26). We recently reported that the
Figure 2. Clinical Outcome
Cumulative incidence curves for death (A), myocardial infarction (B), target ve
and standard therapy groups. Abbreviations as in Figure 1.
Table 6. Baseline Quantitative Coronary Angiography
RA  PES (n 
Before procedure
Lesion length, mm 19.49 9.6
Reference vessel diameter, mm 2.68 0.4
Minimal lumen diameter, mm 1.01 0.3
Diameter stenosis, % 62.23 12.
Immediately after procedure
Minimal lumen diameter, mm
In-stent 2.57 0.3
In-segment 2.26 0.4
Diameter stenosis, %
In-stent 10.79 5.6
In-segment 18.21 8.7
Acute gain, mm
In-stent 1.56 0.4
In-segment 1.24 0.5
Values are mean SD.Abbreviations as in Table 3.TLR rate reached a plateau after 30 months with no further
events thereafter in our RA  DES population (15), which
could be either a play of chance or the result of a particular
vascularization (C), and major adverse cardiac events (D) in the RA  PES
(N  322 Lesions)
Standard Therapy (n  176) p Value
17.99 9.54 0.19
2.76 0.39 0.11
1.10 0.41 0.05
60.19 12.91 0.14
2.55 0.45 0.53
2.29 0.53 0.58
12.34 7.85 0.04
19.09 10.69 0.38
1.44 0.49 0.01
1.19 0.55 0.26ssel reData
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18vessel biology after RA  DES. Long-term follow-up of
he ROTAXUS population may provide further insights
nto this phenomenon.
Clinical implications. This study emphasizes the importance
f careful lesion preparation in complex calcified coronary
esions to ensure stent delivery and complete expansion.
lthough routine RA did not improve DES efficacy, RA
emains an important tool for uncrossable or undilatable
esions and improves overall procedural success in this
etting. A strategy of balloon dilation with provisional
otablation before stenting should remain the default strat-
gy for complex calcified lesions in the DES era.
Study limitations. It should be noted that in using a primary
angiographic endpoint, the conclusions of our trial are
determined on the basis of incomplete observations (80.5%
angiographic follow-up in the current study). This is an
inherent feature of all DES trials using such an angiographic
endpoint. In this regard, concordance of the results of the
secondary endpoint analyses (including TLR), for which
data were available on over 95% of patients, is noteworthy.
We acknowledge that routine angiographic follow-up in-
creases the incidence of TLR in a manner that may not
reflect real-life practice. However, this increases the sensi-
tivity of a study to detect differences in restenosis between
various devices or strategies. This trial was not powered to
detect differences in clinical events, and clinical outcome
data must be interpreted with this in mind. The rather slow
enrollment rate for 3 high-volume centers remains a possi-
ble source of bias.
Conclusions
In this randomized controlled trial, routine rotablation
before PES implantation in complex calcified coronary
Table 7. Nine-Month Follow-Up Quantitative Coronary Angiography Data
(N  255 Lesions)
RA  PES
(n  123)
Standard Therapy
(n  132) p Value
Minimal lumen diameter, mm
In-stent 2.14 0.63 2.25 0.62 0.17
In-segment 1.91 0.57 2.02 0.65 0.17
Diameter stenosis, %
In-stent 22.01 19.92 19.86 19.64 0.35
In-segment 27.92 18.97 26.99 1.73 0.62
Late lumen loss, mm
In-stent 0.44 0.58 0.31 0.52 0.04
In-segment 0.36 0.57 0.25 0.57 0.11
Binary restenosis, %
In-stent 14 (11.4) 14 (10.6) 0.71
In-segment 15 (12.2) 17 (12.9) 0.89
Values are n (%) or mean SD.
Abbreviations as in Table 3.lesions was not superior to PES implantation withoutrotablation in reducing the primary endpoint of LLL at 9
months, indicating that rotablation does not increase the
efficacy of DES in calcified lesions. The superior acute gain
obtained by rotablation was counterbalanced by an increased
late loss resulting in a neutral effect on restenosis. Therefore,
balloon dilation with provisional rotablation before stenting
remains the default strategy for complex calcified lesions in
the DES era.
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